Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin targeted agent vinflunine (VFL) (320 mg m(−2) q 21 days) as second-line chemotherapy in patients with metastatic breast carcinoma (MBC). All patients had disease progression after anthracycline/taxane (A/T)...

Descripción completa

Detalles Bibliográficos
Autores principales: Campone, M, Cortes-Funes, H, Vorobiof, D, Martin, M, Slabber, C F, Ciruelos, E, Bourbouloux, E, Mendiola, C, Delgado, F M, Colin, C, Aslanis, V, Fumoleau, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360552/
https://www.ncbi.nlm.nih.gov/pubmed/17031408
http://dx.doi.org/10.1038/sj.bjc.6603347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360552/
https://www.ncbi.nlm.nih.gov/pubmed/17031408
http://dx.doi.org/10.1038/sj.bjc.6603347

Ejemplares similares